Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas Inc (NQ: ARVN )

23.23 +1.50 (+6.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 361,899
Open 22.11
Bid (Size) 21.78 (1)
Ask (Size) 24.43 (1)
Prev. Close 21.73
Today's Range 21.90 - 23.25
52wk Range 21.21 - 58.58
Shares Outstanding 53,400,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Looking Into Arvinas's Return On Capital Employed
 
Via Benzinga

Performance

YTD
-30.37%
-30.37%
1 Month
-1.19%
-1.19%
3 Month
-24.85%
-24.85%
6 Month
-41.20%
-41.20%
1 Year
-47.50%
-47.50%

More News

Read More
Where Arvinas Stands With Analysts
Via Benzinga
Warner Bros. Discovery To Rally Around 62%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
From Arvinas Inc.
Via GlobeNewswire
Arvinas: Q1 Earnings Insights
Via Benzinga
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at Stifel Targeted Oncology Day
From Arvinas Inc.
Via GlobeNewswire
Arvinas Earnings Perspective: Return On Capital Employed
Via Benzinga
6 Analysts Have This to Say About Arvinas
Via Benzinga
Where Arvinas Stands With Analysts
Via Benzinga
Where Arvinas Stands With Analysts
Via Benzinga
Looking Into Arvinas's Return On Invested Capital
Via Benzinga
Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
Via MarketBeat
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Changes to its Board of Directors
From Arvinas Inc.
Via GlobeNewswire
Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56%
Via Benzinga
Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.